Recombinant Brucella melitensis biotype 1 ATP synthase subunit a (atpB)

Basic Research Questions

• What is Brucella melitensis ATP synthase subunit a (atpB) and why is it significant in research?

ATP synthase subunit a (atpB) is a critical component of the ATP synthase complex in Brucella melitensis, encoded by the atpB gene (locus BMEI1546). This 249-amino acid membrane protein plays an essential role in bacterial energy metabolism by facilitating proton translocation across the membrane during oxidative phosphorylation. As a membrane protein from a significant zoonotic pathogen, atpB represents a potential target for diagnostic, therapeutic, and vaccine development efforts against brucellosis, a disease that poses significant public health problems and economic losses worldwide .

• How is recombinant B. melitensis atpB typically expressed and purified?

Recombinant B. melitensis atpB is typically expressed in Escherichia coli expression systems such as E. coli BL21, similar to other recombinant Brucella proteins . The expression process involves:

• Gene synthesis or PCR amplification of the atpB coding sequence

• Cloning into an appropriate expression vector

• Transformation into E. coli

• Induction of expression under optimized conditions

• Cell harvesting and lysis

• Purification by affinity chromatography (if tagged) or other chromatographic methods

The purified protein is typically stored in a Tris-based buffer with 50% glycerol to maintain stability during storage . Quality control includes SDS-PAGE and Western blotting to confirm purity and identity.

• What structural characteristics of B. melitensis atpB are important for vaccine development?

The atpB protein contains several transmembrane domains with hydrophilic loops that may be exposed and serve as epitopes for immune recognition. According to the amino acid sequence information, the protein consists of 249 amino acids with alternating hydrophobic and hydrophilic regions . For vaccine development, identifying epitopes that can stimulate both humoral and cellular immune responses is critical. Research on other Brucella proteins has demonstrated that specific peptides can induce protective immunity comparable to whole proteins , suggesting that identifying immunodominant epitopes within atpB could lead to effective peptide-based vaccines.

Advanced Research Questions

• What methodologies are recommended for analyzing the immunogenicity of recombinant B. melitensis atpB?

Based on successful approaches with other Brucella antigens, recommended methodologies include:

Researchers should evaluate both humoral and cellular responses, with particular emphasis on Th1-type immunity (IFN-γ, IL-2), which has been shown to be critical for protection against Brucella infection . Spleen cell proliferation assays and cytokine analysis following in vitro stimulation with the recombinant protein provide valuable information about cellular immunity .

• How can researchers assess T-cell epitopes within B. melitensis atpB?

Assessment of T-cell epitopes within atpB should employ a multi-faceted approach:

• In silico prediction using algorithms designed to identify MHC class I and II binding peptides

• Synthesis of overlapping peptides spanning the entire atpB sequence

• T-cell stimulation assays using peptides to identify regions that activate T cells from immunized or infected animals

• Measurement of cytokine production (particularly IFN-γ and IL-2) in response to peptide stimulation

• In vivo T-cell subset depletion studies to determine which T-cell populations recognize specific epitopes

Research on other Brucella proteins has demonstrated that specific peptides can induce protective immunity. For example, a 27-amino acid peptide derived from Omp31 (aa 48-74) induced protection against B. melitensis infection comparable to the whole recombinant protein .

• What are the challenges in developing atpB-based vaccine candidates?

Developing effective atpB-based vaccines presents several challenges:

• Expression and solubility issues: As a membrane protein, atpB may present difficulties in expression and purification while maintaining native conformation.

• Immune response balance: The vaccine must stimulate both humoral and cellular immunity, with emphasis on Th1 responses (IFN-γ, IL-2) critical for Brucella protection .

• Adjuvant selection: The choice of adjuvant significantly impacts immune response quality. Studies with other Brucella proteins have successfully used chitin and incomplete Freund's adjuvant .

• Protective efficacy comparison: New vaccine candidates must demonstrate protection comparable to or better than established vaccines like Rev.1 .

• Cross-protection: The vaccine should ideally protect against multiple Brucella species or strains.

• Epitope accessibility: In smooth Brucella strains, the O-polysaccharide of LPS may hinder access to membrane protein epitopes , potentially limiting vaccine efficacy.

• How do researchers measure protective immunity induced by recombinant B. melitensis proteins?

Protective immunity assessment involves multiple parameters:

Protection is typically quantified by challenging immunized animals with virulent B. melitensis and measuring bacterial burden in the spleen compared to control animals . High levels of IFN-γ and IL-2 production by T cells (particularly CD4+ T cells) correlate with protection against Brucella infection . In vivo depletion of T-cell subsets has revealed that for some Brucella antigens, protection is primarily mediated by CD4+ T cells, with limited contribution from CD8+ T cells .

Methodological Approaches

• What protocols are most effective for designing multi-epitope B. melitensis vaccine candidates?

Effective protocols for designing multi-epitope vaccines include:

• Epitope identification and selection:

  • Identify immunogenic proteins through techniques like 2D gel electrophoresis and MALDI-TOF

  • Use in silico methods to predict B and T cell epitopes within these proteins

  • Select epitopes that induce strong Th1 responses

• Construct design:

  • Connect selected epitopes using appropriate linkers to maintain independent folding

  • Ensure proper spacing and orientation to preserve epitope accessibility

  • Consider codon optimization for the expression system

• Expression and purification:

  • Express in E. coli BL21 or similar systems

  • Purify using appropriate chromatographic methods

  • Verify protein integrity and epitope preservation

• Immunological validation:

  • Test the multi-epitope construct for ability to stimulate both B and T cell responses

  • Compare immune responses to those induced by individual epitopes or whole proteins

  • Assess protective efficacy in animal models

This approach has proven successful with other Brucella antigens. For example, a multi-epitope polypeptide (MEL) containing 19 peptides from various Brucella antigens induced protection comparable to the commercial Rev.1 vaccine .

• How can researchers optimize adjuvant selection for B. melitensis recombinant protein vaccines?

Adjuvant optimization is critical for enhancing vaccine efficacy:

Selection criteria should include:

• Ability to induce Th1-biased responses (crucial for Brucella protection)

• Safety profile for intended host species

• Stability when formulated with the antigen

• Reproducible manufacturing process

Researchers should conduct comparative studies testing different adjuvants with their recombinant protein to identify optimal formulations. The search results indicate that chitin particles activate alveolar macrophages, leading to the expression of cytokines that promote IFN-γ production, making it particularly suitable for Brucella vaccines .

• What analytical methods should be used to characterize recombinant B. melitensis atpB?

Comprehensive characterization requires multiple analytical approaches:

• Physicochemical characterization:

  • SDS-PAGE for purity and molecular weight determination

  • Western blotting for identity confirmation

  • Mass spectrometry for precise molecular weight and sequence verification

  • Circular dichroism for secondary structure assessment

• Functional characterization:

  • ATP synthase activity assays (if functional activity is relevant)

  • Membrane protein reconstitution studies

  • Protein-protein interaction studies with other ATP synthase components

• Immunological characterization:

  • ELISA using sera from infected animals to assess antigenic recognition

  • T-cell stimulation assays to evaluate cellular recognition

  • Epitope mapping to identify immunodominant regions

• Stability assessment:

  • Accelerated and real-time stability studies

  • Freeze-thaw stability

  • Formulation optimization for long-term storage

These methods ensure that the recombinant protein maintains its structural integrity and immunological properties, which are essential for vaccine development and immunological studies.

Research Applications

• How can recombinant B. melitensis atpB contribute to improved diagnostic methods for brucellosis?

Recombinant atpB could enhance brucellosis diagnostics through:

• ELISA-based assays:

  • Development of recombinant protein-based ELISAs for antibody detection

  • Potential for improved specificity compared to traditional tests using bacterial extracts

  • Ability to distinguish vaccinated from infected animals if atpB is not a major component of vaccine strains

• Multiple antigen testing:

  • Inclusion of atpB in multi-antigen panels to improve sensitivity and specificity

  • Combination with other established Brucella antigens for comprehensive detection

• Point-of-care diagnostics:

  • Development of rapid tests using recombinant antigens

  • Field-applicable diagnostics for resource-limited settings

• Cellular immunity assessment:

  • In vitro tests measuring T-cell responses to atpB as indicators of exposure or infection

Current serological methods for brucellosis diagnosis include agglutination tests and ELISA . Recombinant protein-based assays could offer advantages in terms of standardization, specificity, and the ability to differentiate infected from vaccinated animals.

• What is the potential of atpB epitopes for rational vaccine design against B. melitensis?

The potential of atpB epitopes for rational vaccine design includes:

• Peptide-based vaccines:

  • Identification of protective epitopes within atpB could lead to synthetic peptide vaccines

  • Multiple epitopes could be combined into a single construct

  • Research with other Brucella proteins demonstrates that specific peptides can induce protection comparable to whole proteins

• DNA vaccines:

  • Genes encoding atpB epitopes could be incorporated into DNA vaccine constructs

  • Potential for inducing both antibody and T-cell responses

• Vectored vaccines:

  • atpB epitopes could be expressed in viral or bacterial vectors

  • Could enhance presentation to the immune system

• Multi-epitope constructs:

  • Combination of atpB epitopes with epitopes from other Brucella antigens

  • Similar approaches with other antigens have shown promising results

Rational design based on protective epitopes offers advantages over whole-protein approaches, including better targeting of immune responses, reduced risk of adverse reactions, and potential for broader protection against multiple strains or species.

Experimental Design Considerations

• What animal models are most appropriate for evaluating atpB-based vaccine candidates?

Selection of appropriate animal models is critical for vaccine evaluation:

Animal model selection should be based on:

• Study objectives (mechanism investigation vs. efficacy testing)

• Stage of vaccine development

• Available facilities and resources

• Regulatory requirements for eventual approval

Initial screening in mice can identify promising candidates, followed by testing in guinea pigs and eventually in natural hosts. The search results describe successful use of both mice and guinea pigs for evaluating Brucella vaccine candidates.

• How should researchers design studies to compare atpB-based vaccines with commercial vaccines?

Comparative study design should include:

• Experimental groups:

  • atpB vaccine group(s) with different formulations/doses

  • Commercial vaccine positive control (e.g., Rev.1)

  • Adjuvant-only negative control

  • PBS negative control

• Immunization protocol:

  • Standardized dose, route, and schedule

  • Multiple timepoints for immune response assessment

• Challenge protocol:

  • Standardized challenge strain and dose

  • Multiple timepoints for bacterial load assessment

  • Comprehensive tissue sampling

• Assessment parameters:

  • Humoral immunity: antibody titers and isotypes

  • Cellular immunity: cytokine profiles, T-cell responses

  • Protection: bacterial loads in spleen and other tissues

  • Safety: local and systemic adverse reactions

• Statistical analysis:

  • Appropriate sample size determination

  • Rigorous statistical comparison methods

This approach allows direct comparison of new vaccine candidates with established vaccines like Rev.1, which is critical for regulatory approval and acceptance by the scientific community .

• What methodological approaches are most effective for identifying protective mechanisms of atpB-based immunity?

Effective methodological approaches include:

• In vivo T-cell subset depletion:

  • Administration of anti-CD4 or anti-CD8 antibodies during vaccination or challenge

  • Determination of which T-cell subsets are critical for protection

• Adoptive transfer studies:

  • Transfer of immune cells from vaccinated animals to naive recipients

  • Test protection following challenge

  • Identify which cell populations confer protection

• Cytokine neutralization:

  • Administration of antibodies against specific cytokines (e.g., IFN-γ)

  • Assess impact on vaccine-induced protection

• Correlates of protection analysis:

  • Comprehensive immune parameter measurement

  • Correlation with protection levels

  • Identification of biomarkers that predict protection

• In vitro functional assays:

  • Macrophage infection and bacterial killing assays

  • Assessment of antibody opsonization and neutralization

  • T-cell mediated lysis of infected cells

For other Brucella antigens, these approaches have revealed that protection is primarily mediated by CD4+ T cells producing IFN-γ and IL-2, with CD8+ T cells playing a more limited role . Similar methodologies would be valuable for understanding atpB-induced immunity.